PDGFRB and hepatocellular carcinoma: For example, sorafenib, as a multi-RTKs inhibitor that exerts an antiangiogenic effect by VEGFR 2/3 and PDGFR-β, is typically used as the first-line therapy in patients with primary advanced HCC [24, 25].